Duration of action of a chimeric interleukin-2 receptor monoclonal antibody, basiliximab, in pediatric kidney transplant recipients.
Sterkers
G
G
Laboratoire d'Immunologie Biologique, Hôpital Robert Debré, Paris, France.
Baudouin
V
V
Ansart-Pirenne
H
H
Maisin
A
A
Niaudet
P
P
Cochat
P
P
Loirat
C
C
D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics* / Q000627:therapeutic use; D000077552:Basiliximab; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D007223:Infant; D016030:Kidney Transplantation / Q000276:immunology*; D018655:Lymphocyte Count; D011446:Prospective Studies; D015375:Receptors, Interleukin-2 / Q000097:blood* / Q000276:immunology; D011993:Recombinant Fusion Proteins / Q000493:pharmacokinetics / Q000627:therapeutic use; D013997:Time Factors
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D015375:Receptors, Interleukin-2; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab